Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

52.28 +0.60 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Exposures COVID-19 Product Safety
SANOFI-ADR (NASDAQ:SNY) – A Reliable Dividend Stock with Strong Fundamentals
SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors. 
Via Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Earnings Scheduled For April 24, 2025
Via Benzinga
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
Exposures Political US Equities
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations. 
Via Benzinga
Exposures COVID-19
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients. 
Via Benzinga
SANOFI-ADR (NASDAQ:SNY): A Strong Growth Stock with Technical Breakout Potential
SANOFI-ADR (NASDAQ:SNY): A Strong Growth Stock with Technical Breakout Potential 
Via Chartmill
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed. 
Via Benzinga
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated. 
Via Investor's Business Daily
Topics Earnings Government
Exposures Financial Political
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals.
Why the dividend investor may take a look at SANOFI-ADR (NASDAQ:SNY). 
Via Chartmill
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production. 
Via Benzinga
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline. 
Via Benzinga
How Do Investors Really Feel About Sanofi?
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?
Via The Motley Fool
Topics Economy Government World Trade
Exposures COVID-19 Economy Political
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities. 
Via Benzinga
Topics World Trade
Exposures Product Safety Tariff
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response rates and reduced disease flares. 
Via Benzinga
Exposures Product Safety
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
FDA Approves Sanofi's Hemophilia Drug
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year. 
Via Benzinga
Exposures Product Safety
Don't overlook SANOFI-ADR (NASDAQ:SNY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Discover SANOFI-ADR, an undervalued stock. NASDAQ:SNY showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Via Benzinga
Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal
Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with a promising bispecific antibody. 
Via Benzinga
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics.
Why SANOFI-ADR (NASDAQ:SNY) qualifies as a good dividend investing stock. 
Via Chartmill
FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.